In addition, our results demonstrated no nimotuzumab related skin rash was reported in our 42 patients, which could be explained by the property that nimotuzumab has lesser affinity and hence binds with less avidity than other monoclonal EGFR antibodies (cetuximab and panitumumad). This evidence concerns the gene EGFR and exanthem.